Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating

Leerink Partners analyst David Risinger maintained a Buy rating on Xoma (XOMA – Research Report) on May 15 and set a price target of $55.00.

David Risinger has given his Buy rating due to a combination of factors, including Xoma’s strong financial performance and promising pipeline developments. The company’s first-quarter 2025 revenue significantly exceeded expectations, reaching $15.9 million compared to the estimated $8.2 million. This impressive performance was bolstered by milestone payments related to their products tovorafenib and mezagitamab, indicating successful progress in their development stages.
Furthermore, Xoma’s business model, which focuses on collecting royalties, provides a degree of insulation from market volatility, making it an attractive investment. Looking forward, Xoma anticipates several key milestones in 2025, including potential EMA approval for Ojemda and significant data releases for other pipeline products like RZ358 and seralutinib. These upcoming events could further enhance the company’s value, supporting the Buy rating.

According to TipRanks, Risinger is a 5-star analyst with an average return of 7.8% and a 52.60% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Johnson & Johnson, and AnaptysBio.